NasdaqCM - Delayed Quote ? USD XORTX Therapeutics Inc. (XRTX) Follow Compare 1.4300 +0.0150 (+1.06%) At close: 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations XORTX Sponsored Study Presented at the American?Society of Nephrology – Kidney Week 2024 ● Health consequences of chronically high uric acid and xanthine oxidase in polycystic kidney disease in rats, mice and humans ● CALGARY, Alberta, Oct. 24, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American Society of Nephrol GlobeNewswire ? 8 days ago XRTX +1.06% XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement CALGARY, Alberta, Oct. 18, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, today announced that it has closed its registered direct offering and concurrent private placement, announced on October 17, 2024, for the purchase and sale of 810,810 common shares (or pre-funded warrants in lieu thereof) in GlobeNewswire ? 14 days ago XRTX +1.06% XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement CALGARY, Alberta, Oct. 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 810,810 common shares (or common share equivalents in lieu thereof) in a registered direct offering an GlobeNewswire ? 15 days ago XRTX +1.06% XORTX Initiates Precision Medicine Program Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine MetabolismCALGARY, Alberta, Oct. 09, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the Company has initiated a precision medicine program. On August 2 GlobeNewswire ? 23 days ago XRTX +1.06% XORTX Announces Results of?Annual and Special Meeting of Shareholders CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Thursday, September 12, 2024. A total of 889,288 common shares of the Company were represented at the Meeting, represen GlobeNewswire ? last month XRTX +1.06% XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A CALGARY, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has refiled its management’s discussion and analysis (“MD&A”) for the financial year ended December 31, 2023 and for the interim period ended June 30, 2024 as a result of a continuous disclosure review by th GlobeNewswire ? last month XRTX +1.06% XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, reminds shareholders of the upcoming deadline to vote at the Company’s Annual General and Special Meeting (the "Meeting"), which is scheduled to be held on September 12, 2024. The Board of Directors of XORTX recommends that S GlobeNewswire ? last month XRTX +1.06% Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended Shareholders vote “FOR” all the proposed resolutions at the upcoming Annual and Special Meeti GlobeNewswire ? last month XRTX +1.06% XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism ● Xanthine oxidase reported to modulate progression of chronic kidney disease, diabetic kidney disease, polycystic kidney disease, and other indications ● CALGARY, Alberta, Aug. 29, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to report that recent peer-reviewed, independent, published GlobeNewswire ? 2 months ago XRTX +1.06% XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders CALGARY, Alberta, Aug. 23, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the management information circular (the “Circular”) for the annual and special meeting (the “Meeting”) of shareholders is now available on the Company’s website at https://www.xortx.com/investors/news-e GlobeNewswire ? 2 months ago XRTX +1.06% XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024 Health consequences of over active xanthine oxidase may accelerated PKD progressionCALGARY, Alberta, Aug. 20, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American Society of Nephrology (the “ASN”). The abstract entitled "Xanth GlobeNewswire ? 2 months ago XRTX +1.06% XORTX to Present at BIO International Convention 2024 CALGARY, June 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the BIO International Convention 2024, being held June 3rd through 6th, 2024. Dr. Allen Davidoff, XORTX’s CEO, will present an overview on the Company, including the Company’s progress to dat GlobeNewswire ? 4 months ago XRTX +1.06% XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press releases of March 11 and April 30, 2024, the Company has received TSX Venture Exchange (“TSXV”) approval to amend the terms of the balance of outstanding common share purchase warrants (“Warr GlobeNewswire ? 5 months ago XRTX +1.06% XORTX Reprices Warrants Issued in Connection with Previous Private Placements CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press release of March 11, 2024, the Company has received TSX Venture Exchange approval to amend the terms of an aggregate of 1,024,099 outstanding common share purchase warrants (“Warrants”) by GlobeNewswire ? 5 months ago XRTX +1.06% XORTX Announces Publication of Key Research in ADPKD CALGARY, Alberta, April 22, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a research paper titled “Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models" has been accepted for publication in the peer-reviewed American Journal of Phys GlobeNewswire ? 6 months ago XRTX +1.06% XORTX Welcomes New Member to the Board of Directors CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail “Abbey” L. Jenkins, M.S., GlobeNewswire ? 6 months ago GMDA XRTX +1.06% XORTX Announces Participation in Spring 2024 Investor Conferences CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that Dr. Allen Davidoff, CEO, is scheduled to participate in the following Spring 2024 investor and life sciences investment conferences: LD Micro Invitational XIV in New York, April 8-9Management will d GlobeNewswire ? 6 months ago XRTX +1.06% XORTX Announces New Clinical?Advisory Board Member CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“ADPKD”), is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board. Dr. Allen Davidoff stated, “We are excited that Dr. Ron Perrone has agreed to join XORTX’s Clinical Advis GlobeNewswire ? 7 months ago XRTX +1.06% XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide a summary of Company’s achievements in 2023 and objectives planned for 2024. Dr. Allen Davidoff, CEO of XORTX, stated, “2023 marked a year of substantial clinical, technological and regulator GlobeNewswire ? 7 months ago XRTX +1.06% XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, March 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a second tranche closing (the “Second Tranche Closing”) of gross proceeds of CAD $224,850 under previous GlobeNewswire ? 7 months ago XRTX +1.06% Performance Overview Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return XRTX S&P/TSX Composite index YTD -38.10% +15.73% 1-Year -94.17% +28.51% 3-Year -99.37% +15.30%
